EHR

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS...

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab...

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney...

CliniComp Introduces Intrinsic AI™: Revolutionizing Healthcare IT with Native, Clinician-Designed Artificial Intelligence

Seamlessly integrated into CliniComp's advanced EHR Solution Suite, Intrinsic AI™ streamlines workflows, enhances efficiency, and reduces cognitive burden without requiring additional...

FINN Partners and Humble Ventures Expanded ‘Future of Education and Health’ Returns to Austin on Thursday, March 6 – Friday, March 7 at Atelier 1205

Two immersive future-focused days of programming in education and health, bringing together leading innovators, VCs, policymakers, researchers and entrepreneurs for...

HIMSS25: FDB to Spotlight Customer Success Stories and Innovative Drug Knowledge Solutions

From Integrating Real-Time Pharmacogenomics to Boosting Medication Adherence, Healthcare Organizations Are Realizing the Benefits of Advanced Medication Decision Support SOUTH...

error: Content is protected !!